大葉大學圖書館 |

Evaluation of enzyme inhibitors in drug discovery[electronic resource] :a guide for medicinal chemists and pharmacologists /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615/.19
書名/作者:	Evaluation of enzyme inhibitors in drug discovery : a guide for medicinal chemists and pharmacologists // Robert A. Copeland.
作者:	Copeland, Robert Allen.
出版者:	Hoboken, N.J. : : Wiley,, c2013.
面頁冊數:	1 online resource (xxxi, 538 p.)
標題:	Enzyme inhibitors - Therapeutic use
標題:	Drugs - Design.
標題:	Enzyme inhibitors - Structure-activity relationships.
標題:	Enzyme Inhibitors - therapeutic use.
標題:	Drug Design.
標題:	Enzyme Inhibitors - chemistry.
ISBN:	9781118540404 (electronic bk.)
ISBN:	1118540409 (electronic bk.)
ISBN:	9781118540282 (electronic bk.)
ISBN:	111854028X (electronic bk.)
ISBN:	9781118540398 (electronic bk.)
ISBN:	1118540395 (electronic bk.)
書目註:	Includes bibliographical references and index.
摘要、提要註:	"There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
電子資源:	http://onlinelibrary.wiley.com/book/10.1002/9781118540398

Evaluation of enzyme inhibitors in drug discovery[electronic resource] :a guide for medicinal chemists and pharmacologists /
Copeland, Robert Allen.

Evaluation of enzyme inhibitors in drug discoverya guide for medicinal chemists and pharmacologists /[electronic resource] :Robert A. Copeland. - 2nd ed. - Hoboken, N.J. :Wiley,c2013. - 1 online resource (xxxi, 538 p.)

Includes bibliographical references and index.

"There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.

ISBN: 9781118540404 (electronic bk.)

LCCN: 2012046209Subjects--Topical Terms:

588200
Enzyme inhibitors
--Therapeutic use

LC Class. No.: QP601.5 / .C675 2013

Dewey Class. No.: 615/.19

National Library of Medicine Call No.: QU 143

Evaluation of enzyme inhibitors in drug discovery[electronic resource] :a guide for medicinal chemists and pharmacologists /
LDR:02762cam a2200397 a 4500 001 416288
003 OCoLC
005 20130806030035.0
006 m o d
007 cr |||||||||||
008 150205s2013 nju ob 001 0 eng
010 $a 2012046209
020 $a 9781118540404 (electronic bk.)
020 $a 1118540409 (electronic bk.)
020 $a 9781118540282 (electronic bk.)
020 $a 111854028X (electronic bk.)
020 $z 9781118354483 (electronic bk.)
020 $z 1118354486 (electronic bk.)
020 $a 9781118540398 (electronic bk.)
020 $a 1118540395 (electronic bk.)
020 $z 9781118540299
020 $z 1118540298
020 $z 9781118488133 (hardback)
035 $a (OCoLC)818327396
035 $a ocn818327396
040 $a DLC $b eng $c DLC $d YDX $d EBLCP $d N $d E7B $d YDXCP $d OCLCO $d DG1 $d IDEBK $d DG1 $d STF $d DG1 $d UBY
050 4 $a QP601.5 $b .C675 2013
060 1 0 $a QU 143
082 0 0 $a 615/.19 $2 23
100 1 $a Copeland, Robert Allen. $3 588199
245 1 0 $a Evaluation of enzyme inhibitors in drug discovery $h [electronic resource] : $b a guide for medicinal chemists and pharmacologists / $c Robert A. Copeland.
250 $a 2nd ed.
260 $a Hoboken, N.J. : $b Wiley, $c c2013.
300 $a 1 online resource (xxxi, 538 p.)
504 $a Includes bibliographical references and index.
520 $a "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
588 $a Description based on online resource; title from digital title page (viewed on Apr. 25, 2013).
650 0 $a Enzyme inhibitors $x Therapeutic use $x Testing. $3 588200
650 0 $a Drugs $x Design. $3 424032
650 0 $a Enzyme inhibitors $x Structure-activity relationships. $3 588201
650 2 $a Enzyme Inhibitors $x therapeutic use. $3 588202
650 2 $a Drug Design. $3 402272
650 2 $a Enzyme Inhibitors $x chemistry. $3 588203
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9781118540398